pyrazines has been researched along with Chloroma in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, RS; Shields, CL; Wilde, LR; Yaghy, A | 1 |
| Baughn, LB; Janz, S; Linden, MA; Mansoor, A; Stessman, HA; Van Ness, B; Zhan, F | 1 |
| Chen, Z; Hu, S; Rich, A; Tang, G; Wang, W | 1 |
| Bello, C; Cohen, A; Comenzo, RL; Drullinsky, P; Hassoun, H; Hoover, E; Jhanwar, S; Landau, H; Lendvai, N; Lesokhin, A; Nimer, SD; Pandit-Taskar, N; Riedel, E; Schulman, P | 1 |
1 trial(s) available for pyrazines and Chloroma
| Article | Year |
|---|---|
Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Pyrazines; Sarcoma, Myeloid; Survival Rate; Thalidomide | 2012 |
3 other study(ies) available for pyrazines and Chloroma
| Article | Year |
|---|---|
An Iridociliochoroidal Myeloid Sarcoma Associated With Relapsed Acute Myeloid Leukemia With FLT3-ITD Mutation, Treated With Gilteritinib, an FLT3 Inhibitor.
Topics: Administration, Oral; Aniline Compounds; Ciliary Body; Fatal Outcome; fms-Like Tyrosine Kinase 3; Humans; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Pyrazines; Sarcoma, Myeloid; Uveal Neoplasms; Visual Acuity | 2020 |
Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Models, Animal; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Mice; Multiple Myeloma; Prognosis; Pyrazines; Receptors, CXCR4; Sarcoma, Myeloid; Survival Rate | 2013 |
Myeloid sarcoma as the initial presentation of chronic myelogenous leukemia, medullary chronic phase in era of tyrosine kinase inhibitors: A report of 11 cases.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Protein Kinase Inhibitors; Pyrazines; Sarcoma, Myeloid; Survival Analysis | 2015 |